Introduction: The incidence of asthma exacerbations in patients receiving salmeterol/fluticasone propionate ... patients to double the dose of their inhaled corticosteroid medication for a ...

Last year saw a key development in the US respiratory diseases market when Mylan finally launched its generic version of GlaxoSmithKline’s blockbuster inhaler Advair (fluticasone+salmeterol).

The main patent on Advair (fluticasone+salmeterol) expired as long ago as 2010, while the patent on GSK’s Diskus inhaler expired in 2016. But Mylan became the first of a group of potential ...

Background Maintenance and reliever therapy (MART) with inhaled corticosteroid (ICS)/formoterol effectively reduces exacerbations in asthma. We aimed to investigate ...

Asthma–chronic obstructive pulmonary disease (COPD) overlap syndrome (ACOS) is a commonly encountered yet loosely defined clinical entity. ACOS accounts for approximately 15–25% of the ...

Cole Schmidtknecht expected to pay $66.86 for a three-month supply of his preventive asthma inhalers in January 2024 when he ...

Excessive use of reliever inhalers for asthma is linked to a significantly increased risk of dying from the disease, a new study revealed today. Researchers found that over-use of short acting ...

Treatment for two weeks with either oral prednisolone (30 mg/day), high dose fluticasone propionate (2000 μg/day, FP2000), or lower dose FP (500 μg/day, FP500), both given by a dry powder inhaler, ...

After hours: 7:25:23 p.m. EST ...